Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N4JI
|
|||
| Former ID |
DIB006045
|
|||
| Drug Name |
APG-101
|
|||
| Synonyms |
CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix
Click to Show/Hide
|
|||
| Indication | Cerebrovascular ischaemia [ICD-11: 8B1Z; ICD-10: I67.8; ICD-9: 434.91] | Phase 2 | [1] | |
| Company |
Apogenix GmbH
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01071837) APG101 in Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.